Scholar Rock

SRRK

Market cap $3.04B

Overview Fund Activity

31.67 USD

-0.17

0.53%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

32.30

+0.63

1.99%

1 day

-0.53%

5 days

0.57%

1 month

-1.65%

3 months

-4.95%

6 months

-11.51%

Year to date

-28.28%

1 year

283.41%

5 years

92.41%

10 years

104.32%

About: Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Employees: 196

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

34% more call options, than puts

Call options by funds: $32.9M | Put options by funds: $24.5M

33% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 69

15% more capital invested

Capital invested by funds: $3.37B [Q1] → $3.89B (+$516M) [Q2]

11% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 36

4.89% more ownership

Funds ownership: 110.73% [Q1] → 115.61% (+4.89%) [Q2]

1% more funds holding

Funds holding: 230 [Q1] → 233 (+3) [Q2]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$45

42% upside

Avg. target

$48

50% upside

High target

$50

58% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Jefferies Amy Li	$50	Buy Assumed	21 Aug 2025
BMO Capital Etzer Darout	$45	Outperform Maintained	7 Aug 2025

See Analyst Rankings

Financial journalist opinion

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an ag.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an a.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156320) were published in the peer-reviewed journal The Lancet Neurology. The data showed that children and adults with SMA had improve.

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director David L.

Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript

The Motley Fool

Why Scholar Rock Stock Wilted on Wednesday

It didn't take a high-powered academic to figure out why Scholar Rock's (SRRK -5.99%) share price swooned by more than 5% on Wednesday. That morning, the biotech published a quarterly earnings report and business update that fell short of expectations.

Why Scholar Rock Stock Wilted on Wednesday

The Motley Fool

Scholar Rock (SRRK) Q2 Loss Widens 63%

Scholar Rock (SRRK -6.39%), a late-stage biopharmaceutical company specializing in therapies for serious neuromuscular and rare diseases, released its second quarter 2025 earnings on August 6, 2025. The key news was continued preparation for the potential 2025 U.S. launch of apitegromab, its lead muscle-targeted therapy for spinal muscular atrophy (SMA).

Scholar Rock (SRRK) Q2 Loss Widens 63%

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the second quarter ended June 30, 2025. “Our BLA is progressing under priority review towards our September 22 PDUFA date, and our team is working with urgency to prepare.

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

The Motley Fool

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year

On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock (SRRK -0.68%) in an open market transaction.

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that management will host a conference call to discuss its second quarter 2025 financial results and provide a business update on Wednesday, August 6, 2025, at 8:00am ET. To access the live conference call, participants.

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 224,100 shares of its common stock to 6 newly hired employees, consisting of inducement stock options to purchase an aggregate of.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™